Validation of a new strength measurement device for amyotrophic lateral sclerosis clinical trials

被引:29
|
作者
Andres, Patricia L. [1 ]
Skerry, Linda M. [1 ]
Munsat, Theodore L. [2 ]
Thornell, Brenda J. [1 ]
Szymonifka, Jackie [3 ]
Schoenfeld, David A. [3 ]
Cudkowicz, Merit E. [1 ]
机构
[1] Massachusetts Gen Hosp, Neurol Clin Trials Unit, Charlestown, MA 02129 USA
[2] Tufts Med Ctr, Dept Neurol, Boston, MA USA
[3] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA
关键词
ALS; neuromuscular; outcomes measures; reliability; strength testing; VOLUNTARY ISOMETRIC CONTRACTION; NATURAL-HISTORY; ALSFRS-R; SURVIVAL;
D O I
10.1002/mus.22253
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Strength measures with reduced variability and higher sensitivity could improve efficiency in clinical trials of amyotrophic lateral sclerosis (ALS). The Accurate Test of Limb Isometric Strength (ATLIS) was developed to precisely and conveniently measure force in 12 muscle groups. In this study we evaluate the reliability and validity of the ATLIS testing protocol. Methods: Twenty healthy adults and 10 patients with ALS were tested twice by the same or by different evaluators to determine test-retest and interrater reliability. Twenty healthy adults were examined using ATLIS and a wellvalidated strength testing protocol (TQNE) to assess criterionbased validity. Results: Mean absolute variation between tests was 8.6%, and intraclass correlation coefficients for each muscle group were high (range 0.82-0.99). The Pearson correlation coefficient of mean ATLIS and TQNE scores was 0.90. A subject survey demonstrated high user acceptance of ATLIS. Conclusions: ATLIS is convenient for patients and evaluators, produces precise strength measurements, and is easily moved between examining rooms.
引用
收藏
页码:81 / 85
页数:5
相关论文
共 50 条
  • [31] Clinical Neurogenetics Amyotrophic Lateral Sclerosis
    Harms, Matthew B.
    Baloh, Robert H.
    NEUROLOGIC CLINICS, 2013, 31 (04) : 929 - +
  • [32] Amyotrophic lateral sclerosis: a clinical review
    Masrori, P.
    Van Damme, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 (10) : 1918 - 1929
  • [33] Amyotrophic lateral sclerosis: Clinical management and research update
    Andrews, Jinsy
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2009, 9 (01) : 59 - 68
  • [34] Cortical Thinning and Clinical Heterogeneity in Amyotrophic Lateral Sclerosis
    Mezzapesa, Domenico Maria
    D'Errico, Eustachio
    Tortelli, Rosanna
    Distaso, Eugenio
    Cortese, Rosa
    Tursi, Marianna
    Federico, Francesco
    Zoccolella, Stefano
    Logroscino, Giancarlo
    Dicuonzo, Franca
    Simone, Isabella Laura
    PLOS ONE, 2013, 8 (11):
  • [35] Rethinking phase 2 trials in amyotrophic lateral sclerosis
    Benatar, Michael
    Mcdermott, Christopher
    Turner, Martin R.
    van Eijk, Ruben P. A.
    BRAIN, 2025,
  • [36] Staging amyotrophic lateral sclerosis: A new focus on progression
    Corcia, P.
    Beltran, S.
    Lautrette, G.
    Bakkouche, S.
    Couratier, P.
    REVUE NEUROLOGIQUE, 2019, 175 (05) : 277 - 282
  • [37] Beyond the Traditional Clinical Trials for Amyotrophic Lateral Sclerosis and The Future Impact of Gene Therapy
    Cappella, Marisa
    Pradat, Pierre-Francois
    Querin, Giorgia
    Biferi, Maria Grazia
    JOURNAL OF NEUROMUSCULAR DISEASES, 2021, 8 (01) : 25 - 38
  • [38] Performance of the amyotrophic lateral sclerosis functional rating scale (ALSFRS) in multicenter clinical trials
    Cedarbaum, JM
    Stambler, N
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1997, 152 : S1 - S9
  • [39] Respiratory Muscle Strength as a Predictive Biomarker for Survival in Amyotrophic Lateral Sclerosis
    Polkey, Michael I.
    Lyall, Rebecca A.
    Yang, Ke
    Johnson, Erin
    Leigh, P. Nigel
    Moxham, John
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195 (01) : 86 - 95
  • [40] Reconsidering the revised amyotrophic lateral sclerosis functional rating scale for ALS clinical trials
    de Jongh, Adriaan D.
    van den Berg, Leonard H.
    van Eijk, Ruben P. A.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2021, 92 (05): : 569 - 570